繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Scilex Unit Semnur Pharmaceuticals, Denali Capital Sign Merger Agreement

2024-09-03 22:19

10:19 AM EDT, 09/03/2024 (MT Newswires) -- Scilex (SCLX) unit Semnur Pharmaceuticals and Denali Capital Acquisition (DECA) said Tuesday they have signed an agreement for a planned merger which provides for a pre-transaction equity value of Semnur at $2.5 billion.

Upon closing of the deal, the combined company will be renamed Semnur Pharmaceuticals and its shares and warrants are expected to list on Nasdaq under the tickers SMNR and SMNRW, the companies said, adding Scilex would be the majority holder of the combined entity.

The deal is expected to close by Q1 2025.

Semnur is a clinical-late stage pharmaceutical company that develops non-opioid pain treatments.

Scilex shares were up 3% in recent trading.

Price: 1.19, Change: +0.04, Percent Change: +3.48

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。